Mizuho raises Amylyx Pharmaceuticals stock price target to $12 on improved outlook

Mizuho has raised its price target on Amylyx Pharmaceuticals (AMLX) to $12 from $8, maintaining an Outperform rating, citing an improved outlook for its lead asset avexitide in post-bariatric hypoglycemia (PBH) and increasing its market share assumption to 45%. This revision elevates peak risk-unadjusted sales forecasts for avexitide to $1.1 billion and risk-adjusted sales to $665 million. The company, which has seen its shares gain 165% since Mizuho's prior upgrade, is also poised for a near-term catalyst with upcoming Phase 2/3 data for AMX0035 in progressive supranuclear palsy (PSP). This positive sentiment is echoed by other firms, including TD Cowen, Citi, and Goldman Sachs, which also maintain Buy ratings, underscoring strong analyst confidence in AMLX's diverse pipeline and potential for further upside.

Analysis

Amylyx Pharmaceuticals (AMLX) has received a significant vote of confidence from Mizuho, which raised its price target to $12.00 from $8.00 while maintaining an Outperform rating. This revision is underpinned by an enhanced outlook for the company's lead asset, avexitide, for post-bariatric hypoglycemia (PBH), with Mizuho increasing its peak market share assumption to 45% from 35%. Consequently, peak risk-unadjusted sales forecasts for avexitide have been lifted to $1.1 billion, with risk-adjusted forecasts rising to $665 million. The market has already responded favorably to this optimism, with AMLX shares gaining 165% since Mizuho's initial upgrade in April, starkly outperforming the 23% rise in the SPDR S&P Biotech ETF. This bullish sentiment is not isolated; TD Cowen, Citi, and Goldman Sachs have all recently reiterated or initiated Buy ratings, creating a strong analyst consensus around the drug's potential. A key near-term catalyst is the upcoming interim Phase 2/3 data for AMX0035 in progressive supranuclear palsy (PSP). Despite the positive analyst coverage, an InvestingPro analysis notes the company has a FAIR Financial Health Score of 2.49 and negative earnings, introducing a layer of fundamental caution.

Key Decisions for Investors

• Given the strong analyst consensus, upwardly revised sales forecasts for its lead asset avexitide, and Mizuho's projection of ~30% further upside, investors with a higher risk tolerance may find the stock compelling.
• Investors should be mindful that the stock's 165% rally since April has priced in significant optimism, and its current negative earnings and 'FAIR' financial health score warrant careful risk management.
• The upcoming interim Phase 2/3 data for AMX0035 in progressive supranuclear palsy is a critical binary event that could drive significant volatility, making it a key catalyst to monitor for any position in the stock.